Last reviewed · How we verify
Atherosclerosis — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Praluent | ALIROCUMAB | Sanofi | PCSK9 Inhibitor [EPC] | Proprotein convertase subtilisin/kexin type 9 | 2015-01-01 | |
| Colcrys | COLCHICINE | Scilex Pharms | Alkaloid [EPC] | Serine/threonine-protein kinase pim-1 | 1961-01-01 | |
| Praluent | Praluent | Regeneron Pharmaceuticals | Proprotein convertase subtilisin/kexin type 9 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Regeneron Pharmaceuticals · 1 drug in Atherosclerosis
- Sanofi · 1 drug in Atherosclerosis
- Scilex Pharms · 1 drug in Atherosclerosis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Atherosclerosis:
- Atherosclerosis treatment updates — RSS
- Atherosclerosis treatment updates — Atom
- Atherosclerosis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Atherosclerosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/atherosclerosis. Accessed 2026-06-10.
Related
- Atherosclerosis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing